Isogen Life Science B.V.

Isogen Life Science B.V., a Dutch-headquartered company in the Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers sector, has not reported its direct carbon emissions data. However, the company is committed to achieving net-zero or near net-zero greenhouse gas emissions by 2050. These climate commitments are cascaded from a parent organization, as indicated by its status as a current subsidiary.

The targets include:

• Scope 1 emissions: The company aims to reduce its direct greenhouse gas emissions to net zero or near net zero by 2050, from a 2023 baseline.
• Scope 3 emissions: A significant reduction target for Scope 3 emissions is in place, aiming for a 30% reduction by 2027, 35% by 2030, 45% by 2035, and 90% or net-zero emissions by 2050, all against a 2019 baseline.
• Scope 3 upstream emissions: The company has already achieved a 43% reduction in Scope 3 upstream emissions by 2025, from a 2019 baseline, and targets further reductions of 35% by 2030, 45% by 2035, and 90% or net-zero emissions by 2050.

These reduction targets underscore Isogen Life Science B.V.'s commitment to decarbonisation across its operations and value chain.